Summary

Eligibility
for people ages 18-50 (full criteria)
Healthy Volunteers
healthy people welcome
Dates
study started
completion around
Principal Investigator
by Sarah Averbach, MD, MSc

Description

Summary

Gender diverse individuals who use gender-affirming testosterone therapy (GATT) to reduce gender dysphoria may also use progestins for contraception and to manage or suppress uterine bleeding. Research is limited, however, regarding expected bleeding patterns for individuals who choose to initiate GATT concurrently with a progestin. Clinicians who prescribe GATT do not have sufficient data to adequately counsel patients on side effects of concurrent progestin use and therefore extrapolate from studies conducted in cisgender women. This study is a prospective cohort study evaluating bleeding patterns and satisfaction among patients initiating GATT with or without concurrent initiation of a progestin contraceptive. The results from this study will enable clinicians to more accurately counsel patients using GATT on how the use of a progestin might affect their bleeding and whether this differs by progestin method.

Official Title

The Impact of Progestin-only Contraception on Bleeding Patterns in Individuals Initiating Testosterone Therapy for Gender Affirmation

Keywords

Gender, Contraception, progestin, testosterone, gender-affirming, bleeding, Hemorrhage, Bleeding data

Eligibility

You can join if…

Open to people ages 18-50

  • English-speaking currently have a uterus and ovaries
  • desire to initiate GATT
  • potential desire to initiate a progestin (within 14 days of GATT initiation)

You CAN'T join if...

- previous gender-affirming surgery to remove their uterus and/or ovaries

Lead Scientist at UCSD

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Diego
ID
NCT06230770
Study Type
Observational
Participants
Expecting 160 study participants
Last Updated